Immuneering Corp (IMRX) FinancialsIMRXImmuneering Corp

Evaluating the bottom line, Immuneering Corporation maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -33.53%, provide a clear picture of how effectively IMRX converts its operational activities into shareholder value.

In the context of the broader market, IMRX competes directly with industry leaders such as LFCR and EVMN. With a market capitalization of $243.50M, it holds a significant position in the sector. When comparing efficiency, IMRX's gross margin of N/A stands against LFCR's 26.96% and EVMN's N/A. Such benchmarking helps identify whether Immuneering Corporation is trading at a premium or discount relative to its financial performance.

Immuneering has reported zero revenue in multiple quarters, with significant net income losses, such as -$24,192,583 in Q3 2026. However, it has a strong cash position of $182.7 million, providing a runway into 2029 for ongoing operations and development.